Because NF‐κB is a master transcription factor for neuroinflammation in MS and EAE,[93] a growing number of studies have been dedicated to exploring the effect of inhibiting PARP1 activity on the disease course and pathology of MS patients and EAE animals. This evidence concerns the gene NFKB1 and myeloid sarcoma.